ArteraAI, a developer specializing in multimodal artificial intelligence (MMAI) predictive and prognostic cancer tools, has announced a strategic collaborative agreement with GenesisCare, an integrated provider of cancer care services.

Under this partnership, ArteraAI and GenesisCare will collaborate in Australia to generate real-world data through a new clinical trial focused on AI tools guiding treatment decisions.

"We are thrilled to collaborate with GenesisCare to empower the clinical community in Australia in personalizing care for their patients," said Andre Esteva, co-founder and CEO of ArteraAI.

Both ArteraAI and GenesisCare are dedicated to clinical innovation and advancing precision medicine, with a shared goal of enhancing the lives of individuals facing localized prostate cancer.

"Our research partnership with ArteraAI is in line with our commitment to delivering personalized and patient-centric care in communities across Australia," stated Professor Jarad Martin, GenesisCare Radiation Oncologist.

 

Source: businesswire.com

Report Abuse